Caladrius Biosciences, Inc. (NASDAQ: LSTA) reported Q2 EPS of ($0.61), $0.14 better than the analyst estimate of ($0.75).

For earnings history and earnings-related data on Caladrius Biosciences, Inc. (LSTA) click here.